Similarly, receptor status does not vary significantly between primary breast carcinoma and GI metastasis, with 86.3% ER-positive (n=82), 55.4% PR-positive (n=36), and 81.6% (n=40) HER2-negative metastatic tumors, among patients with available information on receptors status (Table 2). Here, ERBB2 is linked to breast carcinoma.